Skip navigation Skip to search.
Hi, Abd al-mohsen Profile Updates Account Info You are signed in as: dalooj_39 Sign OutHelp Upgrade to Safer IE9MailMy Y! Yahoo!.Yahoo! Finance Search Search Web
.What are streaming quotes? { "market" : {"NAME" : "", "ID" : "us", "TZ" : "", "TZOFFSET" : "-14400", "open" : "", "close" : "", "flags" : ""} ,"STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com" ,"arrowAsChangeSign" : false ,"throttleInterval": "1000","localize":"0" ,"region": "US","lang" : "en-US","mu":"1" ,"up_arrow_icon" :"http://l.yimg.com/a/i/us/fi/03rd/up_g.gif" , "down_arrow_icon":"http://l.yimg.com/a/i/us/fi/03rd/down_r.gif" ,"up_color" :"green" , "down_color":"red","pass_market_id" : "0","market_status_yrb" :"YFT_MARKET_WILL_OPEN"}
Home.Investing
Market Overview.Market Stats.Stocks.Mutual Funds.ETFs.Bonds.Options.Industries.Currencies.Education.Commodities...News
Markets.Investing Ideas.Expert Advice.Special Editions.Company Finances.Providers.Video...Personal Finance
Banking & Budgeting.Career & Work.College & Education.Family & Home.Insurance.Loans.Real Estate.Retirement.Taxes.Lifelong Investing...My Portfolios
..Create Portfolio.Market Tracker.Try the New Version!...new!
EXCLUSIVES
Breakout.The Daily Ticker.Daniel Gross.Financially Fit.....Search for share prices
Search for share prices
.Finance SearchThu, May 26, 2011, 7:13AM EDT - U.S. Markets open in 2 hrs 17 mins
...CTI Provides Update on New Product Acquisition Strategy and Upcoming ASCO Events
tweet0EmailPrint..Companies:Cell Therapeutics, Inc.Cell Therapeutics, Inc..Related Quotes
Symbol Price Change
CTIC.MI 1.52 +0.09
Follow these stocks
{"s" : "ctic.mi,cticd","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Cell Therapeutics, Inc. On Thursday May 26, 2011, 1:30 am EDT
SEATTLE, May 26, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ:CTICD - News) today announced that consistent with its previously announced pipeline strategy, CTI has identified a potential acquisition opportunity that is a phase II drug candidate being investigated in the field of cancer immunotherapy. Called antigen presenting cell or APC activators, these protein therapeutics activate macrophages and dendritic cells to present foreign antigens to T-killer cells and T-memory cells thus activating a tumor specific immune attack with potential lifelong immunity against the cancer.
"We are excited by the prospect of potentially acquiring this novel tumor specific and individualized approach for harnessing a patient's immune system to fight and potentially eradicate cancer and look forward to advancing our discussions and due diligence to a point where this product could become an addition to our diversified oncology drug pipeline," said James A Bianco, M.D., CEO of CTI. "With the recent successful outcome of our appeal with the Office of New Drugs at the U.S. Food and Drug Administration (the "FDA"), we have the potential for pixantrone to be approved in the U.S. solely on the basis of the existing PIX301 clinical trial results within six months of our re-submission of our New Drug Application ("NDA") for pixantrone. We believe, along with potential E.U. approval of pixantrone by year end expanding our pipeline with additional novel late stage agents like our recent in-license of tosedostat as well moving into the emerging field of cancer immunotherapy is a smart strategic directive for the continued future growth of CTI. We look forward to updating you on these and other exciting developments in the near future."
ASCO reminder
CTI will have two of its drug candidates as the subject of American Society of Clinical Oncology (ASCO) presentations which include interim data from a study with OPAXIO™ (paclitaxel poliglumex or PPX), in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia ("AML"), which will be presented at the ASCO meeting, June 3-7, 2011 in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.
The OPAXIO study poster will be posted on Friday, June 3, 2011 during the Central Nervous System Tumors session that will be held from 2:00 to 6:00 p.m., and will be part of an oral discussion session from 5:00 to 6:00 p.m. Central Time. The presentation, abstract #2036, is titled, "A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas." The tosedostat study poster will also be posted on Friday, June 3, 2011, during the Leukemia, Myelodysplasia, and Transplantation session that will be held from 2:00 to 6:00 p.m., and will be included in a discussion session from 5:00 to 6:00 p.m. Central Time. The presentation, abstract #6517, is titled, "Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML." The study abstracts are available at
www.asco.org.
CTI to host investor and analyst lunch on novel therapies for hematologic malignancies
CTI will host an investor and analyst event to discuss its drug candidate tosedostat, an oral aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in phase I-II clinical trials, and other novel targeted therapies for hematological malignancies.
Speakers at the event will include Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., and Srdan Verstovsek, M.D., Ph.D., all of the MD Anderson Cancer Center. The event will be held Saturday, June 4, 2011, and the presentation will begin at 11:45 a.m. Central time /6:45 p.m. Central European time/ 9:45 a.m. Pacific time and conclude at approximately 1:00 p.m. Central time /8:00 p.m. Central European time/11:00 a.m. Pacific time. The presentations will be webcast live with slides at
www.celltherapeutics.com.
About OPAXIO(TM)
OPAXIO™ (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX™, is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.
About Tosedostat
Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in phase I-II clinical trials. CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.
Sign up for email alerts and get RSS feeds at our Web site,
http://www.CellTherapeutics.com/investors_alert
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of OPAXIO and tosedostat include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with OPAXIO and tosedostat in particular including, without limitation, the potential failure of OPAXIO to prove safe and effective for the treatment of gliomas, including newly diagnosed high-grade gliomas, the potential failure of tosedostat to prove safe and effective for the treatment of AML, determinations by regulatory, patent, and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing, and selling OPAXIO and tosedostat, that CTI may not be able to obtain FDA and/or European Medicines Agency (the "EMA") approval of pixantrone without conducting an additional clinical trial, that CTI may not be able to obtain FDA and/or approval of pixantrone in the United States or the European Union, that CTI may not be able to FDA and/or EMA approval of pixantrone by year end, that CTI may not be able to obtain FDA approval of pixantrone within six months of resubmission of the NDA, that CTI may not be able to acquire this product candidate, that the product candidate may not activate macrophages and dendritic cells to present foreign antigens to T-killer cells and T-memory cells thus activating a tumor specific immune attack with potential lifelong immunity against the cancer, that the product candidate may not eradicate cancer, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E:
deramian@ctiseattle.com
www.CellTherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E:
invest@ctiseattle.com
www.CellTherapeutics.com/investors
Follow Yahoo! Finance on Twitter; become a fan on Facebook.
Related Headlines
•CTI Provides Update on New Product Acquisition Strategy and Upcoming ASCO Events - PR Newswire
•FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval - PR Newswire
•New OPAXIO and Tosedostat Data Selected for Oral Discussion Sessions at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire
•Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing - PR Newswire
•Italian Stocks - Factors to watch on May 4 - at Reuters
Related Message Boards
•Cell Therapeutics, Inc.
•Cell Therapeutics, Inc.
There are no comments yetPost a comment
Comment Guidelines
Please Enter a Comment 4000 characters remaining
You will be seen as:
Abd al-mohsenAnonymous
Change Photo · Change Name
. Post Comment
Clear
Top Stories
Stocks Get Some Relief From Worries About Greece - AP
G8 leaders gather in France, eyes on Arabs, IMF head - Reuters
Distressed home sales fall in Q1: RealtyTrac - Reuters
Oil at $101 amid weak dollar, mixed demand signs - AP
AdChoices
The Daily Ticker Recent Posts
Better Late Than Never: Regulators Charge Two Traders for 2008 Oil Spike - Aaron Task
Amazon Strikes Back At Apple, Sells Gaga's New Album For $0.99 - Henry Blodget
Calling Web 2.0 a ‘Bubble’ Is Insulting to the Term ‘Bubble’ - Aaron Task
View More
Subscribe to Topics
Top Stories
Add Alert
ctic.mi Headlines
Add Alert
cticd Headlines
Add Alert
See all RSS links
Copyright © 2011 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
.Yahoo! Finance
•Banking & Budgeting
•Calculators
•Currency
•ETFs
•Experts
•Investing
•Insurance
•Market Stats
•Message Boards
•Mobile
•Personal Finance
•What's New
Also on Yahoo!
•Autos
•Finance
•Flickr
•Games
•Groups
•Health
•Mail
•Maps
•Movies
•Music
•My Yahoo!
•News
•Shopping
•Sports
•Travel
•TV
•Video
» All Y! Services
Things To Do
•Read Our Blog
•Finance on Your Phone
•Check Home Values
•Find a New Car
•Search Jobs Across the Web
.Yahoo! Finance Worldwide
ArgentinaAustraliaBrazilCanadaChinaChineseFranceFrench CanadaGermany.Hong KongIndiaItalyJapanKoreaMexicoNew ZealandSingaporeSpainSpanishTaiwanUK & IrelandUSA.Copyright © 2011 Yahoo! All rights reserved. Privacy Policy - About Our Ads - Terms of Service - Copyright Policy - Report Problems - Yahoo! News Network
Quotes delayed, except where indicated otherwise. Delay times are 15 mins for NASDAQ, NYSE and Amex. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page.Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.
Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fundAnalyst estimates data provided by Thomson Financial Network. All data povided by Thomson Financial Network is based solely upon research information provided by third party analysts. Yahoo! has not reviewed, and in no way endorses the validity of such data. Yahoo! and ThomsonFN shall not be liable for any actions taken in reliance thereon.
2142204593